Faron Pharmaceuticals raised €10 million in convertible bonds with favorable terms to extend cash runway and support key research.

Faron Pharmaceuticals issued a second EUR10 million tranche of convertible bonds on December 11, 2025, to an entity managed by Heights Capital Management, with the bonds due in 2028, a 7.5% interest rate, and a conversion price of EUR 2.42256. Proceeds will extend cash runway into Q2 2026 and support its HR MDS study and strategic initiatives. The company says the deal, including special rights, is shareholder-friendly due to favorable terms and limited alternatives.